Despite decades of research and the development of a large group of animal models, our understanding of the mechanisms responsible for the progressive loss of dopamine neurons in Parkinson's disease (PD) is unknown. So-called neuroprotective studies demonstrate that a vast group of molecules readily attenuate the dopamine (DA) neuron loss produced by DA neurotoxin insult. Despite these successes, these neuroprotective strategies have been surprisingly ineffective in patients. This may reflect the fact that the initial pathogenic event and the subsequent disease progression is a consequence of different mechanisms. As we began to think about this disconnect, we discovered that animals exposed to DA neurotoxins exhibited blood-brain barrier (BBB) dysfunction. If the BBB in PD patients is disrupted, then the barrier that normally segregates peripheral vascular factors from brain parenchyma is no longer present. Immune cells could then enter brain and produce a self-perpetuating (progressive) degenerative process. In this review, we propose that peripheral immunity contributes to the degenerative process of PD and may be responsible for the progressive nature of the disease. This hypothesis is supported by a broad and diverse literature that is just beginning to come together to suggest that PD is, in part, an autoimmune disease. In order to understand this hypothesis, the reader must question the conventional wisdom that the BBB is intact in PD, the brain is an immune privileged area, and that pathogenic insult and disease progression may reflect different mechanisms.
INTRODUCTION
likely that the pathogenesis of PD is a consequence of a number of interacting factors (multifactorial; e.g., geneenvironment) and/or multiple exposures (multiple-hit Parkinson's disease (PD) is a progressive neurodegenerative disease that affects approximately 1.5 million hypothesis; e.g., multiple toxins or exposure to the same toxin multiple times) (13) . These proposed risk factors people in the US alone and 6.5 million globally. The disease affects all cultures and races, is more prevalent have been studied in a diverse group of animal models. Pathological evaluation of these animal models as well in males, and primarily affects the elderly (51, 71) . Diagnosis is ordinarily by physical exam, which identifies as patients reveals a clear association between inflammatory events [increased levels of reactive oxygen spe-the cardinal features of tremor, rigidity, akinesia/bradykinesia, and postural instability along with levodopa re-cies (ROS), oxidized proteins, lipids, DNA, and proinflammatory cytokines, as well as activation of microglia sponsiveness. These features are invariably accompanied by a characteristic loss of dopamine (DA)-producing and changes in astrocytes] and the neurodegenerative process. Unfortunately, despite a wealth of research, the neurons in the substantia nigra (SN) as well as degenerative changes in the locus ceruleus, raphe nuclei, and pe-mechanism(s) responsible for the progressive nature of the DA neuron loss remain(s) elusive. Indeed, the vast riphery. Confirmation of the clinical diagnosis at autopsy requires the presence of Lewy bodies. majority of animal models fail to exhibit progression despite neuroinflammatory events that produce neurode-The etiopathogenesis of PD is unknown, although genetic predisposition (26,62) environmental factors, and generative changes that mimic human PD. This suggests the involvement of additional factors. We will argue life styles are thought to contribute (9, 20, 67, 72) . It is here that the neuroinflammation seen in PD compromises participate in the nigral cell degenerative process, then they should be involved in the continued neurodegenera-the integrity of the blood-brain barrier (BBB), which, in turn, facilitates the activation and infiltration of pe-tion as is thought to be the case in patients (46, 53) . However, in most animal models, the activation of mi-ripheral immune cells into brain. This is consistent with the hypothesis that the progressive DA neuron degenera-croglia disappears shortly after toxin exposure, suggesting that although they may be a marker for the neuro-tion that characterizes PD may, in part, involve an autoimmune component.
degenerative process, they alone do not produce the progressive loss that characterizes human PD. Indeed,
INFLAMMATION IN PD
most of the animal models of PD fail to exhibit progressive DA neuron loss, bringing into question the validity Patients with PD as well as animal models of the disease both have clearly documented evidence of neu-of their use as models.
Among the thousands of studies on animals exposed roinflammatory changes. Whether or not these inflammatory events are the cause or a consequence of the to PD risk factors, very few demonstrate progressive DA neuron loss (defined as continued decreases in DA neu-disease remains unclear. However, a recent study by Qin and colleagues (64) demonstrated that exposure to bac-rons well after exposure) even though they all demonstrate microglial activation. The study by Brownell et teriotoxin, lipopolysaccharide (LPS), led to early activation of microglia in rats that was subsequently associ-al. demonstrated that low-dose, intermittent (every other week) chronic MPTP exposure to monkeys over 18 ated with DA neuron loss. This suggests that activation of microglia may precede DA neuron loss and thereby months produced progressive loss of DA signal that continued for 6 months following discontinuation of MPTP be causative. Indeed, autopsied cases of human PD (52), patients exposed to the DA neurotoxin 1-methyl-4-treatment (8) . The animals were stable thereafter. In the same vane, Petroske et al. administered multiple injec-phenyl-1,2,3,6 tetrahydropyridine (MPTP) (46) , and all PD animal models including 6-hydroxydopamine (15) , tions of MPTP with probenicid to prolong the effects of MPTP, and demonstrated progressive reductions in MPTP (76) , rotenone (25, 68) , LPS nigral injection (2, 35) , and prenatal exposure to LPS (49) exhibit micro-several measures of DA function and behavior, although the DA cell counts showed marked recovery after 6 glial activation.
Microglia make up 10% of all glial cells in the brain months (63). Thiruchelvam et al. demonstrated progressive reductions in striatal DA in the 3 months following where they survey the microenvironment. However, these cells are activated by a number of factors and, combined exposure to paraquat and maneb in 18-monthold mice (70) . In addition, targeted overexpression of upon activation, act as phagocytes engulfing debris (57) . Activators include interferon-γ (IFN-γ) (59), tumor ne-human α-synuclein led to progressive DA neuron loss (40, 43) , while treating mice overexpressing α-synuclein crosis factor-α (58), matrix metalloproteinase-3, and aggregated α-synuclein (39, 42, 75) , all of which are ele-with paraquat and maneb caused further DA neuron reductions (70) . Our laboratory demonstrated that suprani-vated in PD and/or its animal models. In addition to phagocytic activity, microglia also release a number of gral infusion of LPS into animals exposed to prenatal LPS led to progressive loss of DA neurons (50) , and Qin substances with known neurotoxic effects, including quinolinic acid, superoxide anions, matrix metallopro-et al. demonstrated that systemic LPS exposure led to DA neuron loss that was initiated well after the insult teinases, nitric oxide, arachidonic acid, chemokines, proinflammatory cytokines, and glutamate (57) . Microglia (64). Although such models are consistent with hypotheses are therefore considered a primary marker of neuroinflammation, although their activities can have beneficial suggesting that low-level exposure to environmental toxins for long periods of time are involved with PD, effects as well. Interestingly, the SN contains 4.5 times as many microglia as other brain regions (38, 47) . These the failure to exhibit sustained progressive neurodegeneration in most animals suggests we are focusing on observations have been used to address one of the key questions associated with the environmental hypotheses only one aspect of the disease. Virtually all of the "neuroprotection studies" have argued that the prevention of of PD, which asks, "if there is systemic exposure to a nonspecific neurotoxin, why are DA neurons more sus-DA neuron loss will treat PD under the misguided assumption that preventing the neurotoxic effects of MPTP ceptible?" If there are more microglia, then it follows that systemic inflammogens would have a more pro-or 6-OHDA has something to do with the progressive loss of DA neurons that likely occurs after the toxic in-nounced effect on the SN, provided they are responsible for the degenerative process. The central involvement of sult (we have fallen prey to the same assumption). When these treatments are subsequently tried in humans, they microglia in the degenerative process is further supported by several studies showing that preventing micro-fail. Although there could be a number of reasons why they fail, it is also possible that preventing the effects of glial activation markedly attenuates DA neuron loss (18, 76) . If microglia are an index of inflammation and the initial toxic insult has little to do with the mecha-nisms responsible for progression of the disease. In our vealed no changes in blood CSF barrier function by examining CSF/serum ratios and oligoclonal bands in PD opinion, this is a critical gap because the patient comes to the office with preexisting disease (ostensibly result-patients (29) . These studies were performed because of evidence of IgG involvement in PD. Even in MS where ing from an insult that took place at some prior time), seeking treatment that will stop the progression. In a immune involvement is widely accepted, however, oligoclonal bands are not always seen. Kurkowska-Jastrzeb-recent review, we suggested that there are numerous reasons why animal models of PD fail to exhibit progres-ska et al. argued that the DA neurotoxin MPTP does not disrupt BBB function (45) . However, unless a detailed sion, not the least of which is that investigators generally do not monitor the animals long enough, because most section-by-section analysis is performed, and was not in this study, IgG immunoreactivity in the brain is difficult assume that acute toxin exposure and DA degeneration is PD (13) . Regardless, if microglia are major markers to detect. O'Callaghan et al. used a single, small administered dose of MPTP (12.5 mg/kg, SC) that did not pro-of neuroinflammation and involved with the neurodegeneration associated with PD, then we have to account duce DA neuron loss and reported no dysfunction of the BBB (61). We too have shown that attenuating DA neu-for the fact that their activation wanes in animal models or that some other neuroinflammatory mechanism may ron loss prevented the MPTP-induced BBB leakage (76) . Canudas et al. injected MPP+ into the SN that pro-underlie the progressive nature of PD.
Another subtype of glia cell found within the brain is duced only a small lesion yet assessed BBB integrity in the striatum with a crude index of BBB integrity (albu-the astrocytes and are generally looked upon more as neuroprotective cells. They provide biochemical support min staining) that could have easily missed an area of leakage given the small size of the lesion produced (10) . for the BBB, play a role in fulfilling the glucose requirement of neurons as well as a role in repair and scarring These studies stand in stark contrast to growing literature as well as a series of studies in our laboratory [now in brain tissue (53). In PD, astrocytes in the SN are reported to upregulate protease-activated receptor-1 (PAR-replicated by Leak et al. (48) ] that revealed consistent punctate leakage of the BBB following treatment with a 1), which serves a protective effect by increasing the activity of glutathione peroxidase, a family of enzymes variety of DA neurotoxins. Faucheux et al. showed an increase in vascular den-known to block oxidative damage (36) . Astrocytes further contribute to neuroprotection by releasing anti-sity in the SN, but not the ventral tegmental (VTA) of PD patients (21), and Barcia et al. provided evidence of inflammatory cytokines, including transforming growth factor-β (TGF-β) and interleukin (IL)-6, as well as neu-microangiogenesis in the PD brain, both of which are associated with barrier dysfunction (4). Kortekaas et al. rotrophic factors such as glial cell line derived neurotrophic factor (GDNF) and fibroblast growth factor used [ 11 C]verapamil imaging to demonstrate an 18% increase in brain uptake in the mesencephalon of PD pa-(FGF) (53). Like microglia, astrocytes are also known to have a Janus face. Thus, astrocytes migrate to sites of tients compared with controls, suggesting increased leakage (44) . Barcia et al. noted an increase in the num-injury and secrete proinflammatory cytokines such as IL-1 and attract activated microglia to sites of injury by ber of blood vessels in close proximity to degenerating DA neurons in nonhuman primates that was highly cor-producing intracellular adhesion molecule 1 (ICAM-1) (56) . The role of astrocytes in the initiation or progres-related with increases in vascular endothelial growth factor (VEGF) expression that induces angiogenesis (4). sion of PD is still unknown and it remains possible that a downregulation of their presumed neuroprotective role Thus, what was once an equivocal literature is now suggestive of vascular changes in PD consistent with BBB could facilitate DA neuron loss and progression. Given that soluble factors released by astrocytes are critical for dysfunction. Moreover, both Westin et al. and Carta et al. demonstrated that dyskinesias in animals were asso-establishing the tight junctions that form the BBB, downregulation of astrocyte function might compromise bar-ciated with increased entry of levodopa into the striatum (11, 74) , and Fuente-Fernandez and colleagues argued rier integrity. Further contributing to this barrier compromise would be microglia-induced neuroinflammation, that dyskinesias were associated with increased DA signaling, ostensibly due to BBB dysfunction (24) . Our lab-which is also known to disrupt BBB integrity. This raises the interesting possibility that BBB dysfunction oratory demonstrated that 6-OHDA in rats and MPTP in mice both produced leakage of FITC-labeled albumin may contribute to disease progression in PD even though conventional wisdom suggests that the BBB is as well as other markers of barrier integrity into brain parenchyma in association with DA-induced neurode-intact.
generation (14, 76) . This barrier compromise was re-THE BBB stricted to areas of active degeneration, not present in nondopaminergic areas (e.g., parietal cortex), whereas Although a number of CNS diseases are associated with compromised BBB function, it is widely believed areas without a BBB (e.g., hypothalamus or area postrema) exhibited leakage independent of DA neurotoxin that this is not the case in PD. Haussermann et al. re-history. This presumed existence of barrier dysfunction phatic drainage pathways and enter the peripheral lymph system to initiate antigen presentation that leads to adap-in PD raises an interesting new question regarding the disease. Would BBB dysfunction facilitate the entry of tive immune activation. Although it appears that peripheral immune mediators can enter an intact brain because peripheral immune cells into areas of active degeneration that then participate in the degenerative process? If of the low level of immune surveillance that normally occurs, it is likely that the inflammation-induced BBB this were the case, then it is also possible that an autoimmune component exists in PD. Interestingly, there is an compromise that led to the release of MBP in the first place would facilitate immune cell entry into the brain. emerging set of parallels between PD and MS where an autoimmune contribution to the neurodegenerative pro-Thus, as was true regarding the BBB in PD, it also may be appropriate to dispel the conventional wisdom that cess is thought to exist. the brain is an immune privileged area. Observations LESSONS FROM MS from MS that degeneration-induced antigen from within the CNS can leak out of the brain, activate the peripheral MS is characterized as a progressive, autoimmune disease of the CNS. The loss of conductance of electri-immune cells, and lead to an autoimmune insult that contributes to disease progression creates an interesting cal signals due to degeneration of oligodentrocytes results in symptoms including muscular weakness, loss of and potential parallel with PD. Thus, degeneration of DA neurons (toxin or other risk factor induced) could coordination, as well as speech and visual disturbances. The underlying cause of MS unknown, but it is thought lead to the release of encrypted antigen (an antigen not seen previously by the immune system and therefore im-to involve dysregulation of the immune system, at least in part (27). munogenic), which then is presented to the adaptive immune system for activation of T and B cells that could In the early stages of MS, oligodendrocyte cell death occurs, releasing myelin basic protein (MBP). This acute then enter the brain across a dysfunctional BBB to produce disease progression. Surprisingly, a review of the phase is associated with activation of microglia followed by the infiltration of immune cells into the CNS. Proin-literature provides sporadic, but consistent, evidence of the presence of immune mediators in the brains of pa-flammatory genes are upregulated, perpetuating neuronal dysfunction and altered trophic support. Further tients and animal models of PD (Table 1) . immune challenges in patients with MS lead to in-PERIPHERAL IMMUNE COMPONENTS IN PD creased recruitment of peripheral immune cells into the CNS, further activating existing microglia, worsening Because T cells appear to play such a significant role in the immune-mediated reactions that underlie MS, we symptoms. Such patients are thought to exhibit a relapsing and progressive form of the disease. Current evi-examined the literature for T-cell involvement in PD. T cells are derived from white blood cells known as dence indicates involvement of autoreactive T cells, B cells, and blood-borne monocytes, which extravasate lymphocytes and play a role in adaptive cell-mediated immunity, which involves the activation of macrophages, from the blood, through a compromised BBB, and into white matter. CD8+ cytotoxic T cells are thought to in-natural killer cells, and antigen-specific cytotoxic T cells, all of which are capable of releasing immune regu-filtrate into the brains where they initiate and sustain the neuroinflammation responsible for demyelination and lating cytokines in response to antigen presentation.
Various subsets of T cells exist, including helper T cells, Wallerian degeneration that leads to progression of disease (60). Soluble factors including complement, proin-cytotoxic T cells, memory T cells, and regulatory T cells.
T cells migrate to the thymus where they mature flammatory cytokines, and myelin-specific autoantibodies have also been implicated in the neural degeneration eventually into T helper cells (CD4+) or cytotoxic T cells (CD8+). Once mature, they are released from the and dysfunction of MS (33,34). It is likely that a dysfunctional BBB contributes to this peripheral immune thymus into the peripheral circulation. In order to become activated, CD4+ and CD8+ cells require the binding of involvement (1, 19, 28, 55, 66, 77) . Support for an autoimmune component in MS is also supported by the well-the T-cell receptor and CD28 with the major histocompatibility complex (MHC) and B7 of the antigen-pres-established animal models of MS, which demonstrate that inoculation of mice with MBP together with im-enting cell. The antigen-presenting cell (APC) must acquire molecules from the environment, process them mune activation produces a MS-like syndrome called experimental allergic encephalomyelitis (EAE). Once into smaller fragments to fit into their MHC class I or class II binding cleft. The APC must then travel to the produced, EAE can be transferred to other animals (adoptive transfer), further supporting the involvement draining lymph node or spleen to present antigen to CD4+ T cells for complete activation of the T cell. Cy-of an immune-mediated mechanism. Data from this model also suggest that released antigen (e.g., MBP), totoxic CD8+ T cells can interact with any APC expressing a MHC class I molecule in circulation. Therefore, can "leak" from cranial nerve rootlets and other lym- the existence of soluble antigens, as well as APCs, is ive" subpopulation, as well as a numeric decrease in B cells, while there was an increase in activated, CD4(+) vital to driving the proinflammatory T-cell response (69). Once activated, these T cells can then attack their CD25(+) lymphocytes in the blood of PD patients (5).
Taken together, these studies appear to paint a consistent antigen-specific targets, producing inflammation.
In the healthy CNS, few T cells enter parenchyma picture of directed T-cell activation in PD patients. Evidence for T-cell involvement in PD is also sup-due to an intact BBB. During disease states such as MS, however, activation of the endothelial cells of the blood ported by studies in animal models. Kurkowska et al.
reported
that CD8+ T cells infiltrated into the ST and vessels by cytokines and increased expression of adhesion molecules on both endothelial cells and lympho-
SN beginning on the first day of treatment and peaked on the day of highest levels of neuronal damage in the cytes set the stage for an adaptive response that allows T-cell entry into the brain. However, this would require MPTP mouse model (44) . Bas et al. demonstrated an increase in CD4+ T cells in the striatum (5). An increase specific activation of lymphocytes against brain antigen crucial for T-cell accumulation at localized areas of of MHC class II antigen expression on microglia as well as infiltration of CD8+ and CD4+ T cells were also ob-damage as well as tropic signals from brain to attract immune mediators to the site of injury (30) . served in the SN and ST after MPTP treatment (45) . Moreover, over half of the T cells observed were re-Interestingly, in PD, data suggests that the overall numbers of T cells are decreased in the blood of PD ported to exhibit CD44 antigen, a glycoprotein involved in cell-to-cell interaction, cell adhesion, and migration. patients as well as in rat models of PD (5,16). This would seem to imply that T cells are not involved. How-In the perhaps greatest parallel to MS, Benner et al. recently reported that nitrated α-synuclein proteins from ever, certain subpopulations of T cells, including CD4+ and CD8+ T cells, are actually increased in the blood of CNS drained into the cervical lymph nodes of MPTPtreated mice where they elicited a T-cell response that PD patients. These cells were also reported to express CD45RO and Fas, markers for activated T cells, which invaded the SN. Ten days following MPTP exposure, IgG was also detected, suggestive of a B-cell response. is indicative of an active immune response (31) . Other studies showed that CD45RA+ "naive" CD4+ subpopu-
In animals with T-and B-cell depletion (SCID mice), MPTP did not produce DA neuron loss, whereas this lation are decreased in association with an increase in the CD45RO+ "memory" CD4+ subpopulation of T loss was reinstated following reconstitution of the SCID mouse immune system. T-cell migration into the SN was cells consistent with the overall reduction in T cells in PD patients described above (23) . Another subset of T only seen in MPTP mice with DA neuron losses. This response could be adoptively transferred when they cells, γ/δ+ T cells, thought to play a role in immune infections and autoimmunity, were also reported to be showed that T cells collected from MPTP-treated mice exacerbated the DA neuron loss produced in recipient elevated in the CSF and blood of PD patients (23) .
More recently, Baba et al. reported significantly de-mice by MPTP and prolonged the neuroinflammatory response. Interestingly, adoptively transferring cells creased CD4+:CD8(+)T-cell ratios, fewer CD4(+)CD 25(+)T cells, and significantly increased ratios of IFN-from MPTP-treated mice to normal control mice did not affect DA cell counts, suggesting the requirement of a γ-producing IL-4-producing T cells in the blood of PD patients, suggesting an immune reaction that may be as-prior nigral insult (6) . This would be consistent with the need for increased levels of tropic molecules capable of sociated with the neuroinflammatory process in the brain (3). Bas et al. similarly reported a numeric decrease in directing the adaptive immune response to the SN and/ or inflammation induced alterations in the BBB. helper T cells, particularly the CD4(+)CD45RA(+) "na-Although the evidence cited above supports the acti-domperidone) and observations in dyskinetic rats suggested increased entry of levodopa (11, 73) , implicating vation of T cells in PD, these cells could only play a role in PD if they were directed into the brain where DA a functional effect. Looking past the conventional wisdom that the brain was an immune privileged structure neurons are located. Evidence for these signals also exists in PD patients and animal models. Thus, in idio-led to the construct where autoimmunity could participate in the disease progression. As we learned more pathic PD, LFA-1, an adhesion molecule found primarily on T cells, but also associated with macrophage and about MS, the parallels seemed obvious. We therefore hypothesize that an autoimmune response directed at neutrophil membranes, is increased in the SN compared with age-matched controls. LFA-1-positive leukocytes products released by the DA neurodegenerative process contributes, at least in part, to the progression that char-were also identified infiltrating the SN (56) . Kalkonde et al. also reported several tropic chemokines, including acterizes PD (Fig. 1 ). In this hypothesis, some factor(s) leads to the degen-CC chemokine ligand 2 (CCL2, monocyte chemoattractant protein-1) and CCL3 (macrophage inflammatory eration of DA neurons. Antigenic materials (i.e., possible product of self-antigens modified by the inflamma-protein-1α), were upregulated in the striatum and the ventral midbrain in the murine MPTP model. The pri-tory process as proposed by Benner) exit the CNS and enter the lymph system where APCs engulf and process mary source of CCL2 and CCL3 in the ST and SN is astrocytes. Dopamine cells also constitutively express them. T cells are subsequently activated, which, in turn, can activate B cells to produce specific antibodies these two chemokines (37). Rentzo et al. also demonstrated increased levels of RANTES, a C-C beta chemo-against these epitopes. These mature T cells expand and circulate. The inflammation within the SN and striatum kine with strong chemoattractant activity for T lymphocytes and monocytes, in serum of PD patients, suggesting that produced the DA degenerative process in the first place will disrupt the integrity of the BBB and signal an the recruitment of activated monocytes, macrophages and T lymphocytes (65) . increase in chemoattractant tropic molecules that direct the entry of the adaptive immune mediators into the lo-The evidence for involvement of B cells in neurodegenerative disease is not as well studied compared with calized areas of active inflammation. The parenchymal inflammatory events will also cause the endothelial cells that for T cells, but does exist. Our group demonstrated that CSF from PD patients as well as those exposed to to downregulate Fas ligand and increase expression of cell adhesion molecules to further facilitate the entry of the DA neurotoxin MPTP showed cross-reactivity with DA neurons (12, 17, 54) . Indeed, 78% of the 77 PD sam-these immune mediators. The entry of these cells will, in turn, lead to more DA neuron cell death associated ples we assessed possessed this DA neuron antibody (DANab). Only one patient in 33 controls was positive.
with further inflammation in a self-perpetuating process. This produces the progressive loss of DA neurons that We argued that the DANab was not responsible for PD, but rather, arose as result of release of encrypted antigen characterizes PD. If the hypothesis above is correct, one should imme-resulting from DA neurodegeneration. Once the DANab was produced, it contributed to disease progression. diately ask: "If this is the case, then animals exposed to MPTP should exhibit progression?" Obviously, they Since these studies, additional evidence has arisen. Husby et al. also demonstrated that IgG isolated from don't. Again, we can look to MS to address this. In an age of inbred animals living in ultraclean animal facili-PD serum killed DA neurons after injection into the SN (32). Immunosuppression reduced the DA neuron toxic-ties, it is clear from the MS literature that immune activation needs to occur in order to make the EAE models ity of MPTP (41) and B-cell and IgG changes have been further documented (5,7), while antibodies to hsp 65 and work. The same argument is likely true in PD models. Thus, the ability of the brain to reverse the ever-present 70 are present in the CSF of PD patients (22). Benner et al. also noted IgG directed at nitrotyrosinated αinflammation that accompanies exposure to DA neurotoxins may simply reflect the lack of peripheral immune synuclein in MPTP mice (6) . The literature thus suggests that peripheral immune mediators and the chemoattrac-activation in these animals. Because the peripheral immune system is in an extremely quiescent state, the acti-tant molecules needed to direct their response is associated with PD. vation of T and B cells and their expansion may not be sufficient to generate adequate numbers of cells to PROPOSED MODEL perpetuate the neurodegenerative process hypothesized above. This could be readily tested by treating MPTP-Assuming that the BBB was dysfunctional in our animal models of PD led us to consider the consequences intoxicated mice with peripheral immune activators (e.g., Freund's adjuvant), endotoxin, or some other bac-of such dysfunction. In our early studies (14) we learned that the leakage we observed increased the entry of terial product that is normally encountered outside of secluded animal facilities. drugs that otherwise would not enter the brain (i.e., Figure 1 . Neurotoxin exposure leads to the degeneration of DA neurons, microglia activation, and blood-brain barrier disruption. The necrotic neuron releases encrypted antigen into peripheral circulation. The antigen then enters the lymph system where antigenpresenting cells engulf and process them. T cells are presented with antigen and become activated which, in turn, can activate B cells to produce specific antibodies against these epitopes. These mature T cells expand and circulate. The inflammation within the SN and striatum that produced the DA degenerative process in the first place will signal an increase in chemoattractant tropic molecules that direct the entry of the adaptive immune mediators into the localized areas of active inflammation. The entry of these cells will lead to more DA neuron cell death associated with further inflammation in a self-perpetuating process.
Arimoto, T.; Bing, G. Up-regulation of inducible nitric
Clearly, this hypothesis is early in development, unoxide synthase in the substantia nigra by lipopolysacchadoubtedly naive in some aspects of its understanding of ride causes microglial activation and neurodegeneration. cell-mediated immunity, and overly simplistic. However, Neurobiol. Dis. 12: 35-45; 2003. it does raise new and very interesting questions regard-
